GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quotient Ltd (OTCPK:QTNTQ) » Definitions » EBITDA

Quotient (Quotient) EBITDA : $-82.78 Mil (TTM As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Quotient EBITDA?

Quotient's EBITDA for the three months ended in Dec. 2022 was $-3.59 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-82.78 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Quotient's EBITDA per Share for the three months ended in Dec. 2022 was $-0.84. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2022 was $-6.87.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Quotient EBITDA Historical Data

The historical data trend for Quotient's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quotient EBITDA Chart

Quotient Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57.22 -73.34 -66.18 -71.62 -84.80

Quotient Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.91 -14.21 -28.70 -36.28 -3.59

Competitive Comparison of Quotient's EBITDA

For the Medical Devices subindustry, Quotient's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quotient's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quotient's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quotient's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Quotient's EBITDA for the fiscal year that ended in Mar. 2022 is calculated as

Quotient's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2022, Quotient's EBITDA was $-84.80 Mil.

Quotient's EBITDA for the quarter that ended in Dec. 2022 is calculated as

Quotient's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2022, Quotient's EBITDA was $-3.59 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Quotient  (OTCPK:QTNTQ) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Quotient EBITDA Related Terms

Thank you for viewing the detailed overview of Quotient's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Quotient (Quotient) Business Description

Traded in Other Exchanges
N/A
Address
Business Park Terre Bonne, Route de Crassier 13, Eysins, CHE, 1262
Quotient Ltd is a commercial-stage diagnostics company. It is involved in the development, manufacturing, and commercialization of conventional reagent products used for blood grouping within the global transfusion diagnostics market. The company develops and commercializes the Mosaiq automation platform. Its product portfolio includes Reagent Red Blood Cells, Antisera Products, Whole Blood Controls, and Ancillary Products. The firm operates in Edinburgh, Scotland, Eysins, Switzerland, and Newton, Pennsylvania. It derives the majority of its revenue from the United States.
Executives
Highbridge Capital Management Llc 10 percent owner 277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Quotient Holdings Finance Co Ltd 10 percent owner C/O APPLEBY GLOBAL SERVICES (CAYMAN) LTD, 71 FORT STREET, PO BOX 500, GRAND CAYMAN E9 KY1-1106
Quotient Holdings Newco, Lp 10 percent owner C/O THE CORPORATION TRUST COMPANY, 1209 ORANGE STREET, WILMINGTON DE 19801
Quotient Holdings Merger Co Ltd 10 percent owner PO BOX 536, 13-14 ESPLANADE, ST. HELIER Y9 JE4 5UR
Quotient Holdings Gp, Llc 10 percent owner C/O THE CORPORATION TRUST COMPANY, 1209 ORANGE STREET, WILMINGTON DE 19801
Isabelle Buckle director C/O QUOTIENT LIMITED, B1, BUSINESS PARK, TERRE BONNE, ROUTE DE CRASSIER 13, EYSINS V8 1262
Prondzynski Heino Von director 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Sophie Bechu director C/O QUOTIENT LIMITED, BUSINESS PARK TERRE BONNE, EYSINS V8 1262
Frederick Hallsworth director THE GARDEN WING, HOUSTON HOUSE, KIRK ROAD, HOUSTON X0 PA6 7AR
Manuel O. Mendez director, officer: Chief Executive Officer 500 PLAZA DRIVE, SECAUCUS NJ 07094
L John Wilkerson director, 10 percent owner C/O GALEN ASSOCIATES, 610 FIFTH AVENUE 5TH FLOOR, NEW YORK NY 10020
Zubeen Shroff director, 10 percent owner C/O HALSEY DRUG CO INC, 1827 PACIFIC STREET, BROOKLYN NY 11233
Ali Kiboro officer: Chief Financial Officer C/O QUOTIENT LIMITED, B1, BUSINESS PARK TERRE BONNE, EYSINS V8 1262
Brian Mcdonough director 12521 MARET DRIVE, ST. LOUIS MO 63127

Quotient (Quotient) Headlines